AI Article Synopsis

  • Current research on how vanadium affects iron-related proteins and iron homeostasis is limited, prompting further investigation into its role in anemia and liver/spleen iron deposition.
  • A study involving rats showed that sodium metavanadate (SMV) and magnesium sulfate (MS) treatments did not significantly change levels of hepcidin or hemojuvelin, though a notable decrease in transferrin receptor 1 was observed only when SMV and MS were combined.
  • The findings suggest that the anemia caused by SMV is likely not related to its impact on hepcidin levels, indicating a need for more research on other potential mechanisms influencing erythropoietin production and iron synthesis.

Article Abstract

Background: The current knowledge about the effects of vanadium (V) on iron (Fe)-related proteins and Fe homeostasis (which is regulated at the systemic, organelle, and cellular levels) is still insufficient.

Objective: This fact and our earlier results prompted us to conduct studies with the aim to explain the mechanism of anemia accompanied by a rise in hepatic and splenic Fe deposition in rats receiving sodium metavanadate (SMV) separately and in combination with magnesium sulfate (MS).

Results: We demonstrated for the first time that SMV (0.125 mg V/mL) administered to rats individually and in conjunction with MS (0.06 mg Mg/mL) for 12 weeks did not cause significant differences in the hepatic hepcidin (Hepc) and hemojuvelin (HJV) concentrations, compared to the control. In comparison with the control, there were no significant changes in the concentration of transferrin receptor 1 (TfR1) in the liver of rats treated with SMV and MS alone (in both cases only a downward trend of 14% and 15% was observed). However, a significant reduction in the hepatic TfR1 level was found in rats receiving SMV and MS simultaneously. In turn, the concentration of transferrin receptor 2 (TfR2) showed an increasing trend in the liver of rats treated with SMV and/or MS.

Conclusions: The experimental data suggest that the pathomechanism of the SMV-induced anemia is not associated with the effect of V on the concentration of Hepc in the liver, as confirmed by the unaltered hepatic HJV and TfR1 levels. Therefore, further studies are needed in order to check whether anemia that developed in the rats at the SMV administration (a) results from the inhibitory effect of V on erythropoietin (EPO) production, (b) is related to the effect of V on the induction of matriptase-2 (TMPRSS6) expression, or (c) is associated with the influence of this metal on haem synthesis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtemb.2020.126550DOI Listing

Publication Analysis

Top Keywords

liver rats
12
rats receiving
8
concentration transferrin
8
transferrin receptor
8
rats treated
8
treated smv
8
rats
7
smv
6
evaluation level
4
level selected
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!